More about the “ARB MI paradox”

AUTOR(ES)
FONTE

BMJ Group

RESUMO

“Logic dictates that angiotensin converting enzyme inhibitors should remain the preferred drug across the entire spectrum of cardiometabolic disease”

Documentos Relacionados